Carbogen Amcis, a Switzerland-based pharmaceutical process development and active pharmaceutical ingredient manufacturing company, has completed and passed US Food and Drug Administration (FDA) inspections at two of its Swiss sites, Aarau and Neuland. The inspections were concluded with no major critical findings, confirming that no concerns were discovered by the FDA.

These inspections follow a series of FDA inspections at the company's sites, including its headquarters in Bubendorf, Switzerland. The Aarau and Neuland facilities are located 10 kilometers away from each other and constitute a team of over 200 employees. The facilities hold a total of 30 vessels ranging from 10 liters to 640 liters in size and are cGMP compliant.

Source: Carbogen Amcis